ReviewComplement-mediated injury and protection of endothelium: Lessons from atypical haemolytic uraemic syndrome
Section snippets
The endothelium
Endothelial cells line the interior surface of all blood vessels in the body, occupying a strategic location between the blood vessel walls and the blood stream. The endothelium is able to detect and respond to mechanical stimuli, such as pressure and shear stress, and to hormonal stimuli such as vasoactive mediators. Endothelial cells have important roles in health and disease. Endothelial cell functions include the release of agents which regulate vasomotor function, trigger inflammatory
Haemolytic uraemic syndrome (HUS)
HUS is a type of thrombotic microangiopathy and is characterised by the formation of fibrin-platelet clots in arterial microcirculations. There is an apparent predilection for the renal glomerular capillaries and arterioles, resulting in kidney failure, although the simultaneous involvement of other microvascular beds in the heart, brain and pancreas to a greater or lesser extent, is recognised and reported in all subtypes of HUS. Endothelial cell injury (swelling, detachment, and
The complement cascade
A principal biological function of the complement system is the rapid recognition and elimination of pathogens. Key mechanisms include opsonisation by C3b, activation of the inflammatory cascade by the generation of the anaphylotoxins C3a and C5a and lysis by the membrane attack complex (MAC; C5b-9). The complement cascade is activated by the classical pathway (CP) (Kojouharova et al. 2010), the alternative pathway (Harboe and Mollnes, 2008, Wallis et al., 2010) or the MBL/MASP pathway (Wallis
Endothelial protection against complement-mediated injury
The complement system is tightly controlled by natural fluid phase and membrane bound inhibitors, to restrict propagation to invading pathogens or altered self cells.
Endothelial cell activation and injury in HUS
Specific insights into the pivotal role of endothelial activation and injury as a trigger and a determinant of outcome in HUS will aid in understanding pathogenic mechanisms. Unravelling the links between genetic predisposition, inflammatory triggers, complement and the coagulation cascade will potentially identify therapeutic pathways with wider relevance for other conditions in which thrombotic vascular injury is a key feature, for example, ischaemia–reperfusion injury (IRI), preeclampsia and
Complement inhibition in aHUS
Current treatment protocols for aHUS are based on plasma exchange/infusion. The rationale for this treatment, which has significantly improved morbidity and mortality in individual cases, but has not been formally evaluated in a clinical trial, is logical. It may beneficially supplement levels of deficient complement components contained in plasma, e.g. Factor H or Factor I, secondly, it removes mutated proteins which may exert a dominant negative effect on complement regulation and thirdly it
Conclusions
Consideration of the interactions between complement and the endothelium is critical for understanding the pathophysiology of conditions with prominent endothelial cell injury. Unanswered questions in aHUS relate to reasons for the renal endothelial susceptibility; the determinants of penetrance in those with a genetic predisposition and the balance between soluble and membrane bound complement regulation at endothelial and basement membrane surfaces. Many aspects of endothelial cell biology
Acknowledgements
The authors gratefully acknowledge the support of their funding bodies. HK is a Medical Research Council Clinical Training Fellow and AR is a Wellcome Trust Intermediate Clinical Fellow. We would also like to thank David Kavanagh, Anne Astier and Jeremy Hughes for their careful consideration and valuable comments on the manuscript.
References (85)
New insights into the etiology of preeclampsia: identification of key elusive factors for the vascular complications
Thromb. Res.
(2011)- et al.
Induction of the cytoprotective enzyme heme oxygenase-1 by statins is enhanced in vascular endothelium exposed to laminar shear stress and impaired by disturbed flow
J. Biol. Chem.
(2009) Glomerular endothelial cell differentiation
Kidney Int.
(2005)- et al.
The endothelium as physiological source of properdin: role of wall shear stress
Mol. Immunol.
(2003) - et al.
Antiphospholipid antibodies bind to activated but not resting endothelial cells: is an independent triggering event required to induce antiphospholipid antibody-mediated disease?
Thromb. Res.
(2004) - et al.
Endothelial cells in physiology and in the pathophysiology of vascular disorders
Blood
(1998) - et al.
Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree
Mol. Immunol.
(2006) - et al.
Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice
Kidney Int.
(2010) - et al.
Structure and function of heparan sulphate proteoglycans
Biochem. J
(1986) - et al.
Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface
J. Biol. Chem.
(1989)
Clusterin: the intriguing guises of a widely expressed glycoprotein
Trends Biochem. Sci.
KLF2-dependent, shear stress-induced expression of CD59: a novel cytoprotective mechanism against complement-mediated injury in the vasculature
J. Biol. Chem.
Heme oxygenase-1 expression enhances vascular endothelial resistance to complement-mediated injury through induction of decay-accelerating factor: a role for increased bilirubin and ferritin
Blood
New insights into the molecular mechanisms of classical complement activation
Mol. Immunol.
Inhibiting complement activation on cells at the step of C3 cleavage
Vaccine
A dietary non-human sialic acid may facilitate hemolytic-uremic syndrome
Kidney Int.
Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulfate proteoglycan
J. Biol. Chem.
Decay-accelerating factor induction on vascular endothelium by vascular endothelial growth factor (VEGF) is mediated via a VEGF receptor-2 (VEGF-R2)- and protein kinase C-alpha/epsilon (PKCalpha/epsilon)-dependent cytoprotective signaling pathway and is inhibited by cyclosporin A
J. Biol. Chem.
Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition
Blood
Factor H mutations in hemolytic uremic syndrome cluster in exons 18–20, a domain important for host cell recognition
Am. J. Hum. Genet.
Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome
Mol. Immunol.
Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome
Blood
Production of biologically active complement factor H in therapeutically useful quantities
Protein Expr. Purif.
TNF-alpha regulation of C3 gene expression and protein biosynthesis in rat glomerular endothelial cells
Kidney Int.
Induction of cellular procoagulant activity by the membrane attack complex of complement
Semin. Cell Biol.
Structure and function of human plasma carboxypeptidase N, the anaphylatoxin inactivator
Int. Immunopharmacol.
A novel mutation in the complement regulator clusterin in recurrent hemolytic uremic syndrome
Mol. Immunol.
Paths reunited: initiation of the classical and lectin pathways of complement activation
Immunobiology
Identification of the second heparin-binding domain in human complement factor H
J. Immunol.
A novel non-synonymous polymorphism (p.Arg240His) in C4b-binding protein is associated with atypical hemolytic uremic syndrome and leads to impaired alternative pathway cofactor activity
J. Immunol.
Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus
Diabetologia
Biosynthesis of complement factor H by human umbilical vein endothelial cells. Regulation by T cell growth factor and IFN-gamma
J. Immunol.
CD59 expressed by human endothelial cells functions as a protective molecule against complement-mediated lysis
Eur. J. Immunol.
Relative roles of decay-accelerating factor, membrane cofactor protein, and CD59 in the protection of human endothelial cells against complement-mediated lysis
Eur. J. Immunol.
Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome
Nat. Med.
Streptococcus pneumoniae-associated hemolytic uremic syndrome
Pediatr. Nephrol.
Expression of complement alternative pathway proteins by endothelial cells. Differential regulation by interleukin 1 and glucocorticoids
Eur. J. Immunol.
CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells
J. Exp. Med.
The development of atypical hemolytic uremic syndrome depends on complement C5
J. Am. Soc. Nephrol.
Thrombomodulin mutations in atypical hemolytic-uremic syndrome
N. Engl. J. Med.
Endothelial dysfunction
J. Am. Soc. Nephrol.
VEGF inhibition and renal thrombotic microangiopathy
N. Engl. J. Med.
Cited by (74)
Complement and coagulation crosstalk – Factor H in the spotlight
2023, ImmunobiologyMore than a key—the pathological roles of SARS-CoV-2 spike protein in COVID-19 related cardiac injury
2023, Sports Medicine and Health ScienceTargeting vascular inflammation through emerging methods and drug carriers
2022, Advanced Drug Delivery ReviewsCitation Excerpt :Endothelial cells tightly regulate cellular and humoral mechanisms of both innate and adaptive immune defense. The membrane-bound complement regulatory proteins, membrane cofactor protein and CD59 are constitutively expressed on healthy endothelial cells, to prevent undesired activation of complement and provide protection against complement-mediated injury [12]. The endothelium is also a key player in maintaining homeostasis of IgG, through the salvage pathway mediated by the neonatal Fc receptor (FcRn) [13–15].
The endocannabinoidome in neuropsychiatry: Opportunities and potential risks
2021, Pharmacological ResearchCitation Excerpt :Several authors investigating the anti-inflammatory effects AEA on microglia in vitro have reported that such effects appear to be mediated by the activation of CB2R and subsequent downregulation of MAPK and NF-κB [521–524]. These findings have been broadly reproduced in studies examining the effects of AEA upregulation in vivo [525–529]. 2-AG also appears to ameliorate neuroinflammation by inhibiting NF-κB production in microglia and subsequent downregulation of PIC production [530–532].
The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy
2021, Cancer Letters